Hematologic Procurement Shared Resource

The Roswell Park Hematologic Procurement Bank (formerly known as the Leukemia Tissue Bank and a part of the Pathology Network Shared Resource) provides researchers and investigators with appropriately procured and cryopreserved samples of bone marrow and peripheral blood cells, DNA, RNA, and serum/plasma samples from patients with hematological malignancies treated at our institute.

Presently, the Bank contains over 100,000 cryopreserved marrow and blood samples from patients with hematological malignancies dating from the present back to 1991 linked to a clinical database. The majority of samples are from patients with acute leukemia. Approximately 70,300 samples from 1,550 individuals with acute myeloid leukemia (AML) and 11,700 samples from 260 patients with acute lymphocytic leukemia (ALL) are currently stored in this shared resource. Samples from patients with myeloid malignancies, chronic leukemias, lymphoproliferative diseases, multiple myeloma, and other hematological disorders are also available.

The Hematological Procurement Bank also contracts with Clinical Research Services to procure, process, and store correlative peripheral blood and other biological samples on patients with a variety of solid and hematological malignancies who are receiving investigational treatment on cancer clinical trials.

Recent Publications

• Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes. Guo Y, Bosompem A, Mohan S, Erdogan B, Ye F, Vickers KC, Sheng Q, Zhao S, Li CI, Su PF, Jagasia M, Strickland SA, Griffiths EA, Kim AS. BMC Genomics. 2015 Sep 24;16(1):727.
  
• Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL. Nature. 2015 Jul 9;523(7559):183-8.
  
• Emadi A, Faramand R, Carter-Cooper B, Tolu S, Ford LA, Lapidus RG, Wetzler M, Wang ES, Etemadi A, Griffiths EA. Presence of isocitrate dehydrogenase (IDH) mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. Am J Hematology, 2015 May; 90(5):E77-9. Epub 2015 Feb 27.
  
• Pharmacological targeting of β-catenin in normal karyotype acute myeloid leukemia blasts. Griffiths EA, Golding MC, Srivastava P, Povinelli BJ, James SR, Ford LA, Wetzler M, Wang ES, Nemeth MJ. Haematologica. 2015 Feb;100(2):e49-52. Epub 2014 Nov 7.
  
• Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Karbach J, Nemeth MJ, Taverna P, Karpf AR, Griffiths EA. Leuk Res. 2014 Nov;38(11):1332-41.
  
• Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia. Lee HJ, Muindi JR, Tan W, Hu Q, Wang D, Liu S, Wilding GE, Ford LA, Sait SN, Block AW, Adjei AA, Barcos M, Griffiths EA, Thompson JE, Wang ES, Johnson CS, Trump DL, Wetzler M. Cancer. 2014 Feb 15;120(4):521-9.